The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 61.50
Bid: 61.00
Ask: 62.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.639%)
Open: 62.00
High: 62.00
Low: 61.50
Prev. Close: 61.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

26 Oct 2020 16:50

RNS Number : 2486D
Tissue Regenix Group PLC
26 October 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

TISSUE REGENIX GROUP PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Harwood Capital Management (Gibraltar) Limited (as investment adviser/manager) to 1.Oryx International Growth Fund Limited

and Harwood Capital LLP (as investment advisor/manager) to 2. Harwood Capital LLP

City and country of registered office (if applicable)

1. Guernsey

2. London, United Kingdom

 

4. Full name of shareholder(s) (if different from 3.)v

Name

1. Oryx International Growth Fund Limited

2. Harwood Capital LLP

 

City and country of registered office (if applicable)

As above

5. Date on which the threshold was crossed or reachedvi:

23/10/2020

6. Date on which issuer notified (DD/MM/YYYY):

26/10/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

 

1. 4.16%

2. 0.18%

 

 

1. 4.16%

2. 0.18%

 

7,032,985,756

Position of previous notification (if

applicable)

1. 2.99%

2. 0.18%

 

 

1. 2.99%

2. 0.18%

 

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00B5SGVL29

 

 

1. 292,700,828

2. 12,500,000

 

 

1. 4.16%

2. 0.18%

 

SUBTOTAL 8. A

305,200,828

4.34%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Christopher Harwood Bernard Mills

4.16%

0

4.16%

Harwood Capital Management Ltd

Harwood Capital LLP

Oryx International Growth Fund Ltd

Christopher Harwood Bernard Mills

0.18%

0

0.18%

Harwood Capital Management Ltd

Harwood Capital LLP

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London

Date of completion

26th October 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAKEKADNEFFA
Date   Source Headline
18th Oct 20177:00 amRNSDirectorate Change
11th Oct 20177:15 amRNSHardman Research: Dual revenue stream growth
28th Sep 20173:15 pmRNSUnaudited Interim Results
8th Sep 20177:00 amRNSNotice of Results
5th Sep 20173:52 pmRNSNotification Of Major Holdings
30th Aug 20175:15 pmRNSIssue of Equity
16th Aug 201712:22 pmRNSHolding(s) in Company
11th Aug 20173:45 pmRNSHolding(s) in Company
11th Aug 20173:37 pmRNSHolding(s) in Company
10th Aug 20174:30 pmRNSHolding(s) in Company
10th Aug 20172:45 pmRNSHolding(s) in Company
10th Aug 20171:10 pmRNSHardman Research: CellRight transforming US growth
10th Aug 201710:10 amRNSHolding(s) in Company
9th Aug 20173:00 pmRNSHolding(s) in Company
9th Aug 20172:30 pmRNSDirector/PDMR Shareholding
8th Aug 20171:41 pmRNSResults of General Meeting and Total Voting Rights
21st Jul 20176:00 pmRNSCirc re.CellRight Acquisition
21st Jul 20178:05 amRNSSuccessful fundraising of £40 million
20th Jul 20176:03 pmRNSProposed Acquisition and Placing
30th Jun 201712:00 pmRNSResult of AGM
2nd Jun 20177:00 amRNSAnnual results for period ended 31 December 2016
31st May 201710:46 amRNSPotential Acquisition Update
19th May 201711:35 amRNSPotential Acquisition
3rd Apr 20177:00 amRNSIssue of Equity
13th Mar 20177:10 amRNSHardman Research: Addressing woundcare in the US
1st Mar 20177:00 amRNSInnovative Technology Contract Awarded
2nd Feb 20177:00 amRNSDermaPure® added to the Federal Supply Schedule
6th Jan 20177:00 amRNSDirectorate Change
9th Dec 20167:15 amRNSHardman Research: a/c change: Not simply 11/12ths
7th Dec 20161:04 pmRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Dec 20167:00 amRNSDermaPure secures GPO agreement with Premier, Inc.
28th Nov 20167:05 amRNSOrthoPureT XT update
22nd Nov 20167:00 amRNSDirectorate Change
12th Oct 20167:00 amRNSInterim Results
28th Sep 20167:00 amRNSNotice of Interim Results
15th Sep 20163:07 pmRNSEdison issues outlook on Tissue Regenix
1st Sep 20167:00 amRNSDermaPure® Medicare coverage in further 10 States
3rd Aug 20167:15 amRNSHardman & Co Research Report on: Tissue Regenix
28th Jul 201610:58 amRNSEdison research outlook on Tissue Regenix (TRX)
18th Jul 201611:20 amRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
11th Jul 20167:00 amRNSOrthopaedics Update
4th Jul 201610:41 amRNSResult of AGM
1st Jul 20167:00 amRNSDermaPure® secures first GPO contract in US
30th Jun 20167:00 amRNSDeferred Annual Bonus Scheme
1st Jun 20167:00 amRNSNew appointment adds clinical expertise to Board
23rd May 20167:00 amRNSPreliminary results for year ended 31 January 2016
20th Apr 20167:00 amRNSNotice of Preliminary Results
14th Apr 20167:00 amRNSChange of Registered Office
24th Mar 20164:40 pmRNSSecond Price Monitoring Extn
24th Mar 20164:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.